BCL2 and diffuse large B-cell lymphoma: Bcl-2 inhibitors were previously suggested by ex vivo and in vivo studies to show beneficial combination effects with ibrutinib in CLL, DLBCL, and MCL [22, 28, 30, 31, 60–62].